Patents Examined by Anoop K. Singh
-
Patent number: 11778994Abstract: A NOD.Cg-PrkdcscidH2rgtm1 Wjl/SzJ.(NOD-scid-IL2r?null, NSG) mouse which is genetically modified such that the en NSG mouse lacks functional major histocompatibility complex I (MHC I) and lacks functional major histocompatibility complex II (MHC II) is provided according to aspects of the present, invention. According to specific aspects the genetically modified NSG mouse, is a NOD.Cg-PrkdcscidH2-K1tml Bpe H2-Ab1eml Mvw H2-D1tml Bpe H2rgtm Wjl/SzJ (NSG-Kb Db)null(IAnull)) mouse, NSG-RIP-DTR (Kb Db)null(IAnull) mouse, or a NOD.Cg-B2mtmlUnePrKdcscidH2dlAb1-E?H2rgtm1 Wjl/SzJ (NSG-B2Mnull(IA IEnull)) mouse. Human, immune cells and/or human: tumor cells are administered to a genetically modified immunodeficient mouse according to aspects described herein and assays of one or more test substances can be performed using the provided mice.Type: GrantFiled: May 14, 2018Date of Patent: October 10, 2023Assignees: The Jackson Laboratory, University of MassachusettsInventors: Michael A. Brehm, Michael V. Wiles, Dale L. Greiner, Leonard D. Shultz
-
Patent number: 11778995Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.Type: GrantFiled: August 21, 2020Date of Patent: October 10, 2023Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)Inventors: Richard Flavell, Till Strowig, Markus G. Manz, Chiara Borsotti, Madhav Dhodapkar, Andrew J. Murphy, Sean Stevens, George D. Yancopoulos
-
Patent number: 11779607Abstract: The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).Type: GrantFiled: May 27, 2022Date of Patent: October 10, 2023Assignee: Avotres, Inc.Inventor: Hong Jiang
-
Patent number: 11779656Abstract: Compositions and regimens useful in treating hemophilia A are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human Factor VIII.Type: GrantFiled: April 13, 2017Date of Patent: October 10, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Lili Wang, James M. Wilson, Jenny Agnes Sidrane
-
Patent number: 11773369Abstract: Spinal cord neural stem cells (NSCs) have great potential to reconstitute damaged spinal neural circuitry. In some embodiments, derivation of spinal cord NSCs from human pluripotent stem cells (hPSCs) is described. These spinal cord NSCs can differentiate into a diverse population of spinal cord neurons comprising multiple positions in the dorso-ventral axis, and can be maintained for prolonged time periods. After grafting into injured spinal cords, grafts may be rich with excitatory neurons, extend large numbers of axons over long distances, innervate their target structures, and enable robust corticospinal regeneration. In some embodiments, hPSC-derived spinal cord NSCs enable a broad range of biomedical applications for in vitro disease modeling, and can provide a clinically-translatable cell source for spinal cord “replacement” strategies in several spinal cord disorders.Type: GrantFiled: August 2, 2019Date of Patent: October 3, 2023Assignee: The Regents of the University of CaliforniaInventors: Hiromi Kumamaru, Mark Tuszynski
-
Patent number: 11773408Abstract: The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.Type: GrantFiled: December 9, 2019Date of Patent: October 3, 2023Inventors: Lucie Carrier, Thomas Eschenhagen, Thomas Voit, Giulia Mearini, Oliver Mueller, Doreen Stimpel
-
Patent number: 11773375Abstract: The present invention is in the field of pluripotent stem cells, more particularly cardiomyocytes derived from pluripotent stem cells. The present invention provides a novel method for differentiating human pluripotent stem cells into a population of cardiomyocytes having an atrial phenotype, and use of said atrial cardiomyocytes for screening of drugs, AF disease model, and others. The method of the invention is particularly useful to generate cardiomyocytes having a more developed or mature atrialphenotype and/or to generate higher yield of cardiomyocytes having an atrialphenotype.Type: GrantFiled: March 27, 2017Date of Patent: October 3, 2023Assignee: Ncardia B.V.Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela, Karin Langenberg
-
Patent number: 11767515Abstract: Disclosed herein are methods for the in vitro differentiation of a precursor cell into definitive endoderm, which may further be differentiated into a human colonic organoid (HCO), via modulation of signaling pathways. Further disclosed are HCOs and methods of using HCOs, which may be used, for example, for the HCOs may be used to determine the efficacy and/or toxicity of a potential therapeutic agent for a disease selected from colitis, colon cancer, polyposis syndromes, and/or irritable bowel syndrome.Type: GrantFiled: December 5, 2017Date of Patent: September 26, 2023Assignee: Children's Hospital Medical CenterInventors: James M. Wells, Jorge Orlando Munera
-
Patent number: 11767538Abstract: The present invention relates to compositions and methods, in particular to methods based on systemic injection of rAAV, for delivering genes to cells of the central nervous system in mammals, such as brain neurons or glial cells, and in particular to motor neurons or glial cells of the spinal cord The invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes. The invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons. The invention may be used in any mammal, including human subjects.Type: GrantFiled: August 9, 2019Date of Patent: September 26, 2023Assignees: GENETHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Martine Barkats
-
Patent number: 11767508Abstract: Described herein are methods, compositions, and kits for directed differentiation of human pluripotent stem cells, neuromesodermal progenitors, and neural stem cells into biomimetic neural tissues comprising one or more rosette structures. Preferably, the methods provided herein direct differentiation of human pluripotent stem cells, neuromesodermal progenitors, and neural stem cells into biomimetic neural tissues comprising a singular neural rosette structure that is comparable to at least a portion of the developing human neural tube. Also described are engineered neural tissue preparations comprising biomimetic neural tissues comprising a singular rosette structure having regional neural progenitor phenotypes.Type: GrantFiled: July 24, 2018Date of Patent: September 26, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Randolph Scott Ashton, Gavin T. Knight
-
Patent number: 11767537Abstract: The present invention relates to an expression system for the heterologous expression of a nucleic acid sequence of interest in a mammalian cell, the system comprising: (i) a first genetic entity, comprising: a nucleic acid sequence encoding a functional Epstein Barr virus nuclear antigen 1 (EBNA-1), the nucleic acid sequence being operably linked to regulatory elements that allow for expression of the nucleic acid sequence encoding a functional EBNA-1; (ii) a second genetic entity, comprising: a nucleic acid sequence encoding a functional nucleoside diphosphate kinase A (NDPK-A), the nucleic acid sequence being operably linked to regulatory elements that allow for expression of the nucleic acid sequence encoding a functional NDPK-A; (iii) a third genetic entity, comprising: the nucleic acid sequence of interest being operably linked to regulatory elements that allow for expression of the nucleic acid sequence of interest; and (iv) a four genetic entity, comprising: the Epstein Barr virus OriP sequence or oneType: GrantFiled: August 25, 2016Date of Patent: September 26, 2023Assignee: LONZA BIOLOGICS PLC.Inventors: Robert Young, James D. Budge, Mark C. Smales
-
Patent number: 11746323Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.Type: GrantFiled: September 25, 2019Date of Patent: September 5, 2023Assignee: ViaCyte, Inc.Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
-
Patent number: 11746331Abstract: An object of the present invention is to provide an endodermal cell population for obtaining optimal somatic cells as cell therapy preparations. The endodermal cell population of the present invention has a reduced content proportion of undifferentiated cells in the cell population and contains endodermal cells differentiable into optimal somatic cells as cell therapy preparations. Further, a somatic cell derived from the endodermal cell population of the present invention has excellent therapeutic effects as a cell therapy preparation.Type: GrantFiled: January 26, 2018Date of Patent: September 5, 2023Assignees: NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINEInventors: Masato Ibuki, Hitoshi Okochi, Shigeharu Yabe
-
Patent number: 11730165Abstract: An organ container includes a bottomed tubular outer container and a bottomed tubular inner container that is fitted into the outer container. A fluid flow path is formed between an outer peripheral surface of the inner container and an inner peripheral surface of the outer container. The outer container has an inlet that communicates between the fluid flow path and the outside, and an outlet that communicates between the fluid flow path and the outside.Type: GrantFiled: July 20, 2020Date of Patent: August 22, 2023Assignee: SCREEN HOLDINGS CO., LTD.Inventors: Shinji Torai, Hiroo Kasamatsu, Syuhei Yoshimoto
-
Patent number: 11723986Abstract: The invention provides for recombinant AAV vectors comprising a miniaturized human micro-dystrophin gene and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from muscular dystrophy.Type: GrantFiled: April 14, 2017Date of Patent: August 15, 2023Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITALInventors: Louise Rodino-Klapac, Jerry R. Mendell
-
Patent number: 11725189Abstract: It is an object to provide a culture method which is capable of maintaining and/or culturing iPS cell-derived intestinal stem cells, while maintaining the properties of intestinal stem cells. The induced pluripotent stem cell-derived intestinal stem cell-like cells are cultured in the presence of a GSK-3? inhibitor, a histone deacetylation inhibitor, and a serum replacement, or in the presence of a GSK-3? inhibitor and a serum replacement. Preferably, the culture is carried out under conditions in which one or more compounds selected from the group consisting of an epidermal growth factor, a TGF? receptor inhibitor and a fibroblast growth factor are further present.Type: GrantFiled: August 20, 2019Date of Patent: August 15, 2023Assignees: PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, FUJIFILM CorporationInventors: Takahiro Iwao, Tamihide Matsunaga, Satoshi Kondo, Shota Mizuno
-
Patent number: 11716974Abstract: The present disclosure provides a chimeric non-human animal comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to screening and identifying metabolites for any type of drugs, typically small molecule drugs, which might affect human liver functions and any other bodily function.Type: GrantFiled: June 27, 2017Date of Patent: August 8, 2023Assignee: Baylor College of MedicineInventors: Karl-Dimiter Bissig, Maria de las Mercedes Barzi Dieguez, Peter Francis Pankowicz
-
Patent number: 11712027Abstract: The present invention relates to a method and facility for breeding insects. According to the invention, the insect breeding facility comprises a spawning area comprising spawning containers which are adapted to receive adult insects and insect food, wherein at least one spawn structure is provided in each spawning container, in which spawn structures the mother insects will spawn their eggs. Furthermore a hatch area is provided in which the eggs will hatch and which allows periodical harvesting of baby larvae from the hatch area. The hatch area comprises a plurality of hatching chambers corresponding in number with the number of batches of spawning containers.Type: GrantFiled: March 10, 2016Date of Patent: August 1, 2023Assignee: YNSECT NL R&D B.V.Inventors: Hans Calis, Pieter Johannes Antonius Franken
-
Patent number: 11708562Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.Type: GrantFiled: October 10, 2019Date of Patent: July 25, 2023Assignee: Janssen Biotech, Inc.Inventors: Alireza Rezania, Jean Xu
-
Patent number: 11702630Abstract: Methods of generating spinal cord glutamatergic interneurons (V2a interneurons) from human pluripotent stem cells (hPSCs) are provided. A method of the present disclosure may include culturing a first population of hPSCs in vitro in a neural induction medium that includes: a retinoic acid signaling pathway activator; a sonic hedgehog (Shh) signaling pathway activator; and a Notch signaling pathway inhibitor, wherein the culturing results in generation of a second population of cultured cells containing CHX10+ V2a interneurons. Also provided are non-human animal models that include the hPSC-derived spinal cord glutamatergic interneurons, and methods of producing the non-human animal models.Type: GrantFiled: May 26, 2017Date of Patent: July 18, 2023Assignees: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, The Regents of the University of California, Georgia Tech Research CorporationInventors: Jessica Butts, Todd C. McDevitt